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(31.4%).The meanhospitalstaywas2 A 2 days.Orelanticoagulationwas
givento 25.7%of patients,whileallpatientsreceivedanantiplateletregimen
(aspirinaloneoraspirinandticlopidine).Proceduralsuccessratewea100%
witha majorcomplicationrateof s.i’~o. Follow-upwasavailablein77.7Y0of
patients.Theclinicallyassessedpatencyratewas85.7%andwas92.8%af-
tera seconddilatationfor restenosis.ThepatencyrateforthePSgroupwee
significantlyhigherthanthatof theWSgroup(1007.vs50%,p < 0.01).Oral
anticoagulationdid not changethe longtermpatencyratefor PSor WS(p
> 0.8).Nostent-inducedemboliccerebrovasculareventsoccurred.Concis-
ion: Subclavianarterystentinghasanexcellentlongtermclinicaloutcome
with antiplatelettherapyalone.The procedure-relatedcomplicationrate is
low.PSseemsto havea morefavorableclinicaloutcomewhencomparedto
WS in the subclavian position.
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G. Dorros,M.Jaff,1.Dorros,A. Lowe,L.Mathiak..% Luke’sMedical
CentefiM/lwaukee,Wisconain,USA
Renal artery stenosis(es) (RAS)were successfullyreveecularizadwith
PalmazNstentsin 123 patients(pts) (age:68 + 9 years)for poorlycon-
trolledhypertensionancflorpreservationof renalfunction:47 pts (39%)had
a baselinecreatinine(Cr)s 1.4mg%;31pts (26%)hada Cr 1S-1.9 mg%;
and42pta(35%)hada Crz 2.0mg%.Sixin-hospitaldeathswereunrelated
to the procedureand occurredin ptewithCr z 2.0 mg%.During36 month
followup,22 pte died: 4 to end-stagerenaldisease,10 to cardiovascular
diseases,4 to cancer,and4 ptsto othercauses.Thecohort’ssurvivalprob-
abilitywas79+ 4%.Survivalwasthenasaessadbystratifyingptsaccording
to baselineCr.
BaselineCreatinins (mg%) Survival(36 mos)
5 1,4 97* 2
1.5-1.9 86 k 6
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the numberof antihypertensivemedications,creatinine(Cr),and sutvival.
Followupdata in each time intervalwee comparedto the patient’sown
baselinemeasurements(pairedcomparison),so as to determinestatistical
significance(*p < 0.05).
Ss8dine 6 mos. 12 mos. 24 mos. 36 mos
SYSTSP(mmHg) 165+26 156&25 154 *30 141 +26” 139 + 20”
DIAST SP (mmHg) 61 &13 S2* 12 80& 15 78& 10 76 k 7
# Medications 2.3 + 1.3 t,9 * 1.0 1.5* 1.0” 1.6 & 0.7 1.1+0.5”
Crestinine(%) 1.9* 1.0 1.7+0.9 1.7+0.6 1.7* 1.2 1.7+0.6
survival(mg%) - 89*5 69*5 79* 6 53* 16
Conclusions:Stent revascularizationof pts with bilateralrenal artery













Of 72 patientsundergoingPTRA,a subsetof 20 (27%)patientspreeentad
with episodicCHF.12/20 (60%)had “global renal ischemia”,with either
bilateralrenalarterystenosisor a solitaryfunctioningkidneyperfusedby a
stenoticrenalarte~. 13patientahadnormalleftventricularejec4ionfraction
(LVEF)andnosignificantvalvularabnormality,asassessedbytransthorecic
echocardiography.Leftventricularhypertrophywas presentin 12 patienta.
Ofthe12patientswithglobalrenalcompromise,9 hadnormalornearnormal
LVEFbutnonethelessdevelopadacuteCHF.
Resu/ts:Atl 20 patients underwent successful PTRA/Palmaz etent de-
ployment under angiographic and intravascular ultrasound (IVUS) guidance.
Patients had six month clinical follow upand 17/20(65%)hadangiographic,
IVUS,andhemodynamicfollowup.TherewasnorecurrenceofCHFin18/20
(90
pressuredroppedfrom 188+ 30/92+ 14 mmHg to 147+ 18/78+ 11mm
Hg[p= 0.002]at sixmonths,on fewerantihypertensivemedications(3.7+




the presenceof underlyingrenal atiery stenosia.(2) Patientswith global
renalischemia(bilateralrenalarterystenosisorcompromiaadflowto solitary
functioningkidney)commonlymaypresentas CHF.(3) PTRAwith Palmaz
stentdeploymentis an effectivemeanaof managingCHFassociatedwith
RAS.(4) In presenceof reducedLVEFand RAS,ACE-1is betrertolerated
afterrenalarterystenting.
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Tocomparethe efficacyof ACEinhibitionand diuretictherapyin reducing
blocdpressure(BP)andleftventricular(LV)mass,50essentialhypertensive
(74% male, 88% non-white)were treatad in a double-blind,randomized
mannerforsixmonthswitheitherramiprfl(upto20 mg)orhydrochlorothiazide
(HCTZ;upto60mg).EchoCardiographyandambulatoryBPmonitoringwere
performedat baselineand3 and6 monthsafterinitiationof therapy.The22
ramiprtlpatientswerecomparabletothe26HCTZpatientsatbaselineinage,
race,24-hourBPandLVmassindexbutweremorelikelyto be women(41
vs14%,p < 0.05).AlthoughHCTZresultedina greaterreductionin24-hour
BP(145/93to 132E4vs153A36to147/91mmHg;-9.1/–9.1 vs -3.2!-4.7%
change,p < 0.05),onlytreatmentwith ramiprilresultedin decreasesin LV
mass(193to 179,p <0.005, vs 1S4to 162gm,NS),massindex(103.6to
94.9,p <0.001,vs92.7t091.9gWm2,NS)andmasa/heigh~7(48.5t044.8,
p <0.005, vs41.1to 40.9grn/m27,NS.LVmassdecreasewasattributable
to a reductionin wallthicknessesbutnot chamberdiameter.In multivariate
analysis,bothchangein BPanddruggroupwereindependentpredictors(p
< 0.03)of changein LVmass.
In conclusion,althoughdiuretictherapywassignificantlymoreeffective
in loweringambulatoryBPin this predominantlynon-whitepopulation,only
therapywithACEinhibitionwasassociatedwithsignificantregressionof LV
mass.
